Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MAGE-A1-specific TCR cells + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MAGE-A1-specific TCR cells | MAGE-A1-specific TCR-transduced autologous T cells | MAGE-A1-specific TCR cells consist of autologous T-lymphocytes that are engineered to express a T-cell receptor that recognizes the human melanoma antigen 1 (MAGE-A1), which potentially inhibits growth of MAGE-A1-expressing tumor cells (NCI Drug Dictionary). | ||
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04639245 | Phase Ib/II | MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | Terminated | USA | 0 |